Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.55 |
| ▸ | CA2 | P00918 | 9/20 | 0.55 |
| ▸ | CA9 | Q16790 | 8/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 3/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CA5A | P35218 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL329795 | 0.85 | ALDH1A1 (0.47) | CA1CA2CA9MAOAALDH1A1 | |
| SCHEMBL29945034 | 0.83 | MAOA (0.47) | MAOACDK2ALDH1A1GLAKDM4E | |
| SCHEMBL329796 | 0.83 | MAOA (0.47) | MAOACDK2ALDH1A1GLAKDM4E | |
| SCHEMBL6987366 | 0.83 | MAOA (0.45) | CA1CA2CA9MAOAALDH1A1 | |
| SCHEMBL22011703 | 0.79 | CDC14B (0.49) | MAOAALDH1A1GLAKDM4ECYP3A4 | |
| SCHEMBL10583631 | 0.74 | CA1 (0.62) | CA1CA2CA9MAOACA12 | |
| SCHEMBL9138970 | 0.74 | CDK2 (0.78) | CA1CA2CA9CDK2CA12 | |
| SCHEMBL7599675 | 0.73 | MAOA (0.41) | MAOAALDH1A1GLAKDM4ECYP3A4 | |
| SCHEMBL2195718 | 0.72 | MAOA (0.54) | CA1CA9MAOACA12ALDH1A1 | |
| SCHEMBL7943736 | 0.72 | MAOA (0.56) | MAOAALDH1A1GLAKDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080254130-A1 | Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction | BIODERM RESEARCH (US) | 2008-10-16 | — | — | US | disclosed |
| US-20060074108-A1 | Matrix metalloprotease (MMP) inhibitors and their application in cosmetic and pharmaceutical composition | BIODERM RESEARCH (US) | 2006-04-06 | — | — | US | disclosed |
| EP-1233017-B1 | Tricyclic sulfonamides useful as matrix metalloproteinase inhibitors | WARNER LAMBERT CO (US) | 2005-12-14 | — | — | EP | disclosed |
| US-6906092-B2 | Method of inhibiting matrix metalloproteinases | WARNER-LAMBERT COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| US-6906092-B2 | Method of inhibiting matrix metalloproteinases | WARNER-LAMBERT COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040029945-A1 | Method of inhibiting matrix metalloproteinases | O'BRIEN PATRICK MICHAEL (US) | 2004-02-12 | — | — | US | disclosed |
| US-20040029945-A1 | Method of inhibiting matrix metalloproteinases | O'BRIEN PATRICK MICHAEL (US) | 2004-02-12 | — | — | US | disclosed |
| US-6624177-B1 | Treating diseases in which matrix melatoproteinases are involved such as multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurism, heart failure, periodontal disease, corneal ulceration, burns, decubital | WARNER-LAMBERT COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-6624177-B1 | Treating diseases in which matrix melatoproteinases are involved such as multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurism, heart failure, periodontal disease, corneal ulceration, burns, decubital | WARNER-LAMBERT COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-6620835-B2 | Sulfonamide-substituted benzothiophenes (that may be oxidized), carbazoles, fluorenes and fluorenones | WARNER-LAMBERT COMPANY | 2003-09-16 | — | — | US | disclosed |
| EP-0931045-A1 | MATRIX METALLOPROTEINASE INHIBITORS AND THEIR THERAPEUTIC USES | WARNER-LAMBERT COMPANY (US) | 1999-07-28 | — | — | EP | disclosed |
| EP-0931045-A1 | MATRIX METALLOPROTEINASE INHIBITORS AND THEIR THERAPEUTIC USES | WARNER-LAMBERT COMPANY (US) | 1999-07-28 | — | — | EP | disclosed |
| EP-0929542-A1 | COMPOUNDS FOR AND A METHOD OF INHIBITING MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1999-07-21 | — | — | EP | disclosed |
| EP-0870764-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1998009957-A1 | COMPOUNDS FOR AND A METHOD OF INHIBITING MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |
| WO-1998009934-A1 | MATRIX METALLOPROTEINASE INHIBITORS AND THEIR THERAPEUTIC USES | WARNER-LAMBERT COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |
| WO-1998009934-A1 | MATRIX METALLOPROTEINASE INHIBITORS AND THEIR THERAPEUTIC USES | WARNER-LAMBERT COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |
| US-5571821-A | CARDIOVASCULAR DISORDERS TO MODULATE ENDOTHELIN, HYPOTENSIVE AGENTS AND VASOCONSTRICTION | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-11-05 | — | — | US | disclosed |
| EP-0699191-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-03-06 | — | — | EP | disclosed |
| WO-1994027979-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | IMMUNOPHARMACEUTICS, INC. (US) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029945-A1 | Method of inhibiting matrix metalloproteinases | MMP17, MMP1, MMP12 | CA1 118/4885CA2 501/4885CA9 423/4885 |
| US-20080254130-A1 | Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction | PSMB1, PLOD3, CUTA | CA1 4867/4885CA2 4627/4885CA9 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.